GlassScriptPhysician profile
Mohammed N Kanaan
NPI 1326270992
$636.46
in general payments reported to CMS, 2019-2025
16 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.24 · 2020: $36.60 · 2021: $11.92 · 2022: $90.00 · 2023: $65.53 · 2024: $180 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.43 |
| Education | $100.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.81 | 2024-2025 | |
| Tempus Ai, INC | $131.32 | 2024-2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $69.23 | 2023-2025 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $58.28 | 2022-2025 | Opdivo |
| Sumitomo Pharma America, INC. | $43.10 | 2024 | Orgovyx |
| Incyte Corporation | $42.61 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $39.66 | 2022-2023 | Imbruvica |
| Exelixis INC. | $22.75 | 2019 | |
| Rigel Pharmaceuticals, INC. | $21.39 | 2020 | |
| Coherus Oncology, INC. | $15.21 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Kanaan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.